Overview

Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept

Status:
Active, not recruiting
Trial end date:
2021-10-29
Target enrollment:
Participant gender:
Summary
This will be a single center, randomized, parallel group, repeated dose study of recifercept (Cohort 1 and Cohort 2) or placebo (only in Cohort 1) in approximately 18 healthy participants, using 2 cohorts (N = 9) at two dose levels of recifercept.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer